Citations

Clear

1526 citation(s) found for "Sun, Yu".

Postvaccination Symptoms After a Fourth Dose of mRNA SARS-CoV-2 Vaccination in Patients With Inflammatory Bowel Disease
Lee, Yoo Jin , Li, Dalin , Debbas, Philip , Hampton, Melissa, Ebinger, Joseph E. , Chiorean, Michael , Lum, Donald , Damas, Oriana M. , Melmed, Gil , Group, CORALE-IBD Study, Banty, Andrea, Feldman, Edward J., Ha, Christina , Lee, Susie, Rabizadeh, Shervin , Stein, Theodore , Solomon, Theodore, Syal, Gaurav , Targan, Stephan R. , Vasiliauskas, Eric, Ziring, David , Bonthala, Niru, Botwin, Gregory S, Khanishian, Elizabeth, Pozdnyakova, Valeriya , Gu, Phillip , White, Shane , Zamudio, Cindy, Gonzalez, Daniel , Parry, Alyssa, Hanna, Mary , Chan, Justin, Ebinger, Joe , Wu, Min , Hoang, Amy, Wynter, Timothy , Sun, Nancy , Figueiredo, Jane C. , Merchant, Akil , Merin, Noah , Appel, Keren , Boland, Brigid S. , Charabaty, Aline , Cohen, Erica , Flynn, Ann D. , Valentine, John F. , Ehrlich, Adam C., Fudman, David , Horizon, Arash, Karayev, Dmitry, Kretzmann, Benjamin, Hou, Jason K. , Hwang, Caroline, Lazarev, Mark , Fausel, Rebecca, Reddy, Swapna , McConnell, Ryan , Mattar, Mark , Metwally, Mark, Ostrov, Arthur, Parekh, Nimisha, Raffals, Laura H., Sheibani, Sarah , Younes, Ziad , Braun, Jonathan , Melmed, Gil Y , Mujukian, Angela , Mengesha, Emebet , Cheng, Susan , McGovern, Dermot , Group, CORALE-IBD Study, Botwin, Gregory J., White, Shane, Joung, Sandy , Hoang, Amy, Reckamp, Karen L. , Kumar, Rashmi , Rubin, David T. , Siegel, Corey A , Wolf, Douglas C.

Mayo Clinic

Inflammatory Bowel Diseases | September 29, 2023 | Volume: 30 | Issue: 8 | Pages: 1430-1434

10.1093/ibd/izad198 | PMID 37773982 Get It

Discrete class I molecules on brain endothelium differentially regulate neuropathology in experimental cerebral malaria
Fain, Cori E. , Zheng, Jiaying , Jin, Fang, Ayasoufi, Katayoun , Wu, Yue , Lilley, Meredith T. , Dropik, Abigail R. , Rodriguez, Robert C , Aibaidula, Abudumijiti, Tritz, Zachariah P. , Bouchal, Samantha M. , Pewe, Lecia L. , Urban, Stina L. , Chen, Yin, Chang, Su-Youne , Hansen, Michael J. , Kachergus, Jennifer M., Shi, Ji , Thompson, E. Aubrey , Jensen, Hadley E, Harty, John T. , Wu, Long‐Jun , Johnson, Aaron J. , Wolf, Delaney M. , Tritz, Zachariah P , Parney, Ian F , Wu, Long-Jun , Johnson, Aaron J. , Ayasoufi, Katayoun , Lilley, Meredith T , Dropik, Abigail R , Zheng, Jiaying , Bouchal, Samantha M , Parney, Ian F. , Sun, Jie

Mayo Clinic

Brain | September 28, 2023 | Volume: 147 | Issue: 2 | Pages: 566-589

10.1093/brain/awad319 | PMID 37776513 Get It

Abstract Cerebral malaria is the deadliest complication that can arise from Plasmodium infection. CD8 T-cell engagement of brain vasculature is a putative mechanism of neuropathology in cerebral malaria. To define contributions of brain endothelial cell major histocompatibility complex (MHC) class I antigen-presentation to CD8 T cells in establishing cerebral malaria pathology, we developed novel H-2Kb LoxP and H-2Db LoxP mice crossed with Cdh5-Cre mice to achieve targeted deletion of discrete class I molecules, specifically from brain endothelium. This strategy allowed us to avoid off-target effects on iron homeostasis and class I-like molecules, which are known to perturb Plasmodium infection. This is the first endothelial-specific ablation of individual class-I molecules enabling us to interrogate these molecular interactions. In these studies, we interrogated human and mouse transcriptomics data to compare antigen presentation capacity during cerebral malaria. Using the Plasmodium berghei ANKA model of experimental cerebral malaria (ECM), we observed that H-2Kb and H-2Db class I molecules regulate distinct patterns of disease onset, CD8 T-cell infiltration, targeted cell death and regional blood–brain barrier disruption. Strikingly, ablation of either molecule from brain endothelial cells resulted in reduced CD8 T-cell activation, attenuated T-cell interaction with brain vasculature, lessened targeted cell death, preserved blood–brain barrier integrity and prevention of ECM and the death of the animal. We were able to show that these events were brain-specific through the use of parabiosis and created the novel technique of dual small animal MRI to simultaneously scan conjoined parabionts during infection. These data demonstrate that interactions of CD8 T cells with discrete MHC class I molecules on brain endothelium differentially regulate development of ECM neuropathology. Therefore, targeting MHC class I interactions therapeutically may hold potential for treatment of cases of severe malaria.
Eplontersen for Hereditary Transthyretin Amyloidosis With Polyneuropathy
Coelho, Teresa , Dasgupta, Noel R., Parman, Yeşim , França, Marcondes C. , Guo, Yuh‐Cherng , Wixner, Jonas , Ro, Long‐Sun , Calandra, Cristian , Kowacs, Pedro André , Weiler, Markus , Jung, Shiangtung W., Büchele, Gustavo, Chen, Jersey , Hughes, Steven G. , Schneider, Eugene, Viney, Nicholas J. , Masri, Ahmad , Gertz, Morie R., Ando, Yukio, Khella, Sami, Dyck, P. James B. , Investigators, NEURO-TTRansform, Gane, Edward , Dávila, Lucía Galán, Mezei, Michelle M. , Moreno, Juan González, Cintas, Pascal , Traub, Rebecca , Khoury, Julie, Estol, Conrado J. , Polydefkis, Michael , Brannagan, Thomas H., Rugiero, Marcelo, Distad, B. Jane, Papanicolaou, Eleni Zamba, Lin, Kon‐Ping, Benson, Merrill D., Scheinberg, Morton , Gillmore, Julian D , Marques, Wilson , Chao, Chi‐Chao , Berk, John L. , Obici, Laura , Barroso, Fábio , Conceição, Isabel , Brambatti, Michela , Gertz, Morie A. , Ando, Yukio, Gillmore, Julian D. , Waddington‐Cruz, Márcia , Investigators, NEURO-TTRansform, Mazzeo, Anna Teresa , Papagianni, Aikaterini E. , Dimachkie, Mazen M. , Zaganas, Ioannis V. , Luigetti, Marco , Pareyson, Davide , Needham, Merrilee , Adams, David , Bril, Vera , Attarian, Shahram , Lin, Kon‐Ping

Mayo Clinic

JAMA | September 28, 2023 | Volume: 330 | Issue: 15 | Pages: 1448

10.1001/jama.2023.18688 | PMID 37768671 Get It

Importance Transthyretin gene silencing is an emerging treatment strategy for hereditary transthyretin (ATTRv) amyloidosis. Objective To evaluate eplontersen, an investigational ligand-conjugated antisense oligonucleotide, in ATTRv polyneuropathy. Design, Setting, and Participants NEURO-TTRansform was an open-label, single-group, phase 3 trial conducted at 40 sites across 15 countries (December 2019-April 2023) in 168 adults with Coutinho stage 1 or 2 ATTRv polyneuropathy, Neuropathy Impairment Score 10-130, and a documented TTR variant. Patients treated with placebo from NEURO-TTR ( NCT01737398 ; March 2013–November 2017), an inotersen trial with similar eligibility criteria and end points, served as a historical placebo (“placebo”) group. Interventions Subcutaneous eplontersen (45 mg every 4 weeks; n = 144); a small reference group received subcutaneous inotersen (300 mg weekly; n = 24); subcutaneous placebo weekly (in NEURO-TTR; n = 60). Main Outcomes and Measures Primary efficacy end points at week 65/66 were changes from baseline in serum transthyretin concentration, modified Neuropathy Impairment Score +7 (mNIS+7) composite score (scoring range, –22.3 to 346.3; higher scores indicate poorer function), and Norfolk Quality of Life Questionnaire–Diabetic Neuropathy (Norfolk QoL-DN) total score (scoring range, –4 to 136; higher scores indicate poorer quality of life). Analyses of efficacy end points were based on a mixed-effects model with repeated measures adjusted by propensity score weights. Results Among 144 eplontersen-treated patients (mean age, 53.0 years; 69% male), 136 (94.4%) completed week-66 follow-up; among 60 placebo patients (mean age, 59.5 years; 68% male), 52 (86.7%) completed week-66 follow-up. At week 65, adjusted mean percentage reduction in serum transthyretin was −81.7% with eplontersen and −11.2% with placebo (difference, −70.4% [95% CI, −75.2% to −65.7%]; P < .001). Adjusted mean change from baseline to week 66 was lower (better) with eplontersen vs placebo for mNIS+7 composite score (0.3 vs 25.1; difference, −24.8 [95% CI, −31.0 to −18.6; P < .001) and for Norfolk QoL-DN (−5.5 vs 14.2; difference, −19.7 [95% CI, −25.6 to −13.8]; P < .001). Adverse events by week 66 that led to study drug discontinuation occurred in 6 patients (4%) in the eplontersen group vs 2 (3%) in the placebo group. Through week 66, there were 2 deaths in the eplontersen group consistent with known disease-related sequelae (cardiac arrhythmia; intracerebral hemorrhage); there were no deaths in the placebo group. Conclusions and Relevance In patients with ATTRv polyneuropathy, the eplontersen treatment group demonstrated changes consistent with significantly lowered serum transthyretin concentration, less neuropathy impairment, and better quality of life compared with a historical placebo. Trial Registration ClinicalTrials.gov Identifier: NCT04136184 ; EU Clinical Trials Register: EudraCT 2019-001698-10
Characteristics of Human Nasal Turbinate Stem Cells under Hypoxic Conditions
Kim, Do Hyun , Kim, Sun Hong , Park, Sang Hi , Kwon, Mi Yeon , Lim, Chae-Yoon, Park, Sun Hwa , Gwon, Kihak , Hwang, Se Hwan , Kim, Sung Won , Gwon, Kihak , Kim, Do Hyun , Hwang, Se Hwan

Mayo Clinic

Cells | September 26, 2023 | Volume: 12 | Issue: 19 | Pages: 2360

10.3390/cells12192360 | PMID 37830573 Get It

This study investigated the influence of hypoxic culture conditions on human nasal inferior turbinate-derived stem cells (hNTSCs), a subtype of mesenchymal stem cells (MSCs). It aimed to discern how hypoxia affected hNTSC characteristics, proliferation, and differentiation potential compared to hNTSCs cultured under normal oxygen levels. After obtaining hNTSCs from five patients, the samples were divided into hypoxic and normoxic groups. The investigation utilized fluorescence-activated cell sorting (FACS) for surface marker analysis, cell counting kit-8 assays for proliferation assessment, and multiplex immunoassays for cytokine secretion study. Differentiation potential—osteogenic, chondrogenic, and adipogenic—was evaluated via histological examination and gene expression analysis. Results indicated that hNTSCs under hypoxic conditions preserved their characteristic MSC phenotype, as confirmed by FACS analysis demonstrating the absence of hematopoietic markers and presence of MSC markers. Proliferation of hNTSCs remained unaffected by hypoxia. Cytokine expression showed similarity between hypoxic and normoxic groups throughout cultivation. Nevertheless, hypoxic conditions reduced the osteogenic and promoted adipogenic differentiation potential, while chondrogenic differentiation was relatively unchanged. These insights contribute to understanding hNTSC behavior in hypoxic environments, advancing the development of protocols for stem cell therapies and tissue engineering.
Anesthesia and Critical Care for the Prediction and Prevention for Small-for-size Syndrome: Guidelines from the ILTS-iLDLT-LTSI Consensus Conference
Rajakumar, Akila , Shingina, Alexandra , Yoon, Uzung , Patel, Dhupal , Spiro, Michael , Bhangui, Pooja , Sun, Li-Ying, Humar, Abhinav , Findlay, James Y. , Saigal, Sanjiv , Rodríguez-Dávalos, Manuel I. , Kumar, Lakshmi , Kumaran, Vinay , Agarwal, Shaleen , Egawa, Hiroto , Lerut, Jan , Bröering, Dieter C. , Berenguer, Marina , Cattral, Mark S. , Clavien, Pierre‐Alain , Chen, Chao‐Long , Shah, Samir, Zhu, Zhi‐Jun , Ascher, Nancy L. , Emond, Jean C. , Rela, Mohamed , Findlay, James, Berenguer, Marina , Chadha, Ryan , Sakai, Tetsuro , Bezinover, Dmitri , Singh, Shweta A , Yi, Nam‐Joon , Berlakovich, Gabriela , Bhangui, Prashant , Rammohan, Ashwin

Mayo Clinic

Transplantation | September 26, 2023 | Volume: 107 | Issue: 10 | Pages: 2216-2225

10.1097/tp.0000000000004803 | PMID 37749811 Get It

Background. During the perioperative period of living donor liver transplantation, anesthesiologists and intensivists may encounter patients in receipt of small grafts that puts them at risk of developing small for size syndrome (SFSS). Methods. A scientific committee (106 members from 21 countries) performed an extensive literature review on aspects of SFSS with proposed recommendations. Recommendations underwent a blinded review by an independent expert panel and discussion/voting on the recommendations occurred at a consensus conference organized by the International Liver Transplantation Society, International Living Donor Liver Transplantation Group, and Liver Transplantation Society of India. Results. It was determined that centers with experience in living donor liver transplantation should utilize potential small for size grafts. Higher risk recipients with sarcopenia, cardiopulmonary, and renal dysfunction should receive small for size grafts with caution. In the intraoperative phase, a restrictive fluid strategy should be considered along with routine use of cardiac output monitoring, as well as use of pharmacologic portal flow modulation when appropriate. Postoperatively, these patients can be considered for enhanced recovery and should receive proactive monitoring for SFSS, nutrition optimization, infection prevention, and consideration for early renal replacement therapy for avoidance of graft congestion. Conclusions. Our recommendations provide a framework for the optimal anesthetic and critical care management in the perioperative period for patients with grafts that put them at risk of developing SFSS. There is a significant limitation in the level of evidence for most recommendations. This statement aims to provide guidance for future research in the perioperative management of SFSS.
You are not lab rats at teaching hospitals: A systematic review of resident and fellow participation leads to improved colonoscopy
Chen, Yue , Ma, Shaodi , Liu, M. , Yau, Vicky , Kim, Na Hyun , Kailas, Sujatha, Lowe, Scott , Bentley, Rachel , Chen, Shuya , Liu, Jie , Meng, Muzi , Huang, Yuting , Zhou, Qin , Wu, Yuyan , Liu, Mengqing , Huang, Yuting , Sun, Chenyu

Mayo Clinic

Journal of Evidence-Based Medicine | September 22, 2023 | Volume: 16 | Issue: 3 | Pages: 332-341

10.1111/jebm.12554 | PMID 37735811 Get It

AbstractBackgroundParticipation in colonoscopies is an essential aspect of endoscopic training. The purpose of this study was to explore the impact of fellow/trainee participation on colonoscopy outcomes.MethodsThis meta‐analysis was registered on the International Prospective Register of Systematic Reviews (PROSPERO). From database inception to July 2022, studies investigating fellow involvement and colonoscopy outcomes were searched across Cochrane library, PubMed, and other databases. The random‐effects model was applied to generate more conservative estimates. Sensitive analysis was conducted to explore whether the result would depend on a particular study. Egger's test and Begg's test were used to estimate the potential for publication bias.ResultsSeventeen studies including 30,062 participants were included. We found that fellow/trainee involvement enhanced the overall rates of adenoma detection and polyp detection (OR = 1.26, 95% CI = 1.14–1.40, p < 0.001; OR = 1.29, 95% CI = 1.02–1.63, p = 0.020, respectively). The mean number of adenoma/polyps per colonoscopy was also higher with fellow/trainee participation (MD = 0.12, 95% CI = 0.08–0.17, p < 0.001; MD = 0.15, 95% CI = 0.02–0.28, p = 0.020, respectively).ConclusionIn addition to its educational purpose, fellow or trainee involvement is associated with beneficial effects on colonoscopy outcomes.
A randomized, double-blind, placebo-controlled trial of aldafermin in patients with NASH and compensated cirrhosis
Rinella, Mary E. , Lieu, Hsiao D., Goodman, Zachary , Alkhouri, Naim , Abdelmalek, Manal F. , Wong, Vincent Wai‐Sun , Younes, Ziad , Sheikh, Aasim , Brannan, Donald, Freilich, B., Membreno, Fernando E., Sinclair, Marie , Melchor‐Khan, Liza, Ling, Lei , Abdelmalek, Manal , Wong, Vincent Wai-Sun , Rinella, Mary , Kowdley, Kris V. , Lawitz, Eric , Ratziu, Vlad , Brannan, Donald, Sanyal, Arun J. , Harrison, Stephen A.

Mayo Clinic

Hepatology | September 21, 2023 | Volume: 79 | Issue: 3 | Pages: 674-689

10.1097/hep.0000000000000607 | PMID 37732990 Get It

Background and Aims: Aldafermin, an engineered analog of the human hormone FGF19, improves liver histology in patients with noncirrhotic NASH; however, its efficacy and safety in compensated cirrhosis is unknown. No drug has yet to demonstrate benefit in the compensated NASH population. Approach and Results: In this multicenter, double-blind, placebo-controlled, phase 2b trial, 160 patients with compensated NASH cirrhosis were randomized to aldafermin 0.3 mg (n = 7), 1 mg (n = 42), 3 mg (n = 55), or placebo (n = 56) for 48 weeks. The 0.3 mg group was discontinued to limit exposure to suboptimal doses. The primary end point was a change in Enhanced Liver Fibrosis from baseline to week 48. The analyses were performed in the intention-to-treat population. At week 48, the least-squares mean difference in the change in Enhanced Liver Fibrosis was −0.5 (95% CI, −0.7 to −0.2; p = 0.0003) between the 3 mg group and the placebo group. 15%, 21%, and 23% of patients in the placebo, 1 mg, and 3 mg group, respectively, achieved fibrosis improvement ≥ 1 stage; and 13%, 16%, and 20% achieved fibrosis improvement ≥ 1 stage without NASH worsening. Improvement in alanine aminotransferase, aspartate aminotransferase, neoepitope-specific N-terminal pro-peptide of type III collagen, and liver stiffness favored aldefermin groups over placebo. Diarrhea was the most frequent adverse event, occurring at 26% and 40% in the 1 mg and 3 mg groups, respectively, compared to 18% in the placebo group. Overall, 0%, 2%, and 9% of patients in the placebo, 1 mg, and 3 mg group, respectively, discontinued due to treatment-related adverse events. Conclusions: Aldafermin 3 mg resulted in a significant reduction in Enhanced Liver Fibrosis in patients with compensated NASH cirrhosis.
ATP1A3 as a target for isolating neuron-specific extracellular vesicles from human brain and biofluids
You, Yang , Zhang, Zhengrong , Sultana, Nadia , Ericsson, Maria , Martens, Yuka A. , Sun, Min , Kanekiyo, Takahisa , Ikezu, Seiko , Shaffer, Scott A. , Ikezu, Tsuneya , Ikezu, Tsuneya , Yang, You , Shaffer, Scott , Sultana, Nadia

Mayo Clinic

Science Advances | September 15, 2023 | Volume: 9 | Issue: 37 | Pages: No page available

10.1126/sciadv.adi3647 | PMID 37713494 Get It

Neuron-derived extracellular vesicles (NDEVs) are potential biomarkers of neurological diseases although their reliable molecular target is not well established. Here, we demonstrate that ATPase Na + /K + transporting subunit alpha 3 (ATP1A3) is abundantly expressed in extracellular vesicles (EVs) isolated from induced human neuron, brain, cerebrospinal fluid, and plasma in comparison with the presumed NDEV markers NCAM1 and L1CAM by using super-resolution microscopy and biochemical assessments. Proteomic analysis of immunoprecipitated ATP1A3 + brain-derived EVs shows higher enrichment of synaptic markers and cargo proteins relevant to Alzheimer’s disease (AD) compared to NCAM1 + or LICAM + EVs. Single particle analysis shows the elevated amyloid-β positivity in ATP1A3 + EVs from AD plasma, providing better diagnostic prediction of AD over other plasma biomarkers. Thus, ATP1A3 is a reliable target to isolate NDEV from biofluids for diagnostic research.
Patient-Reported Outcomes of Omission of Breast Surgery Following Neoadjuvant Systemic Therapy
Lin, Heather , Diego, Emilia J. , Yang, Wei , Valero, Vicente , Mitchell, Melissa P. , White, Richard L. , Rauch, Gaiane M., Kuerer, Henry M. , Group, Exceptional Responders Study, Moseley, Tanya W. , Leung, Jessica WT, Huang, Monica L. , Arribas, Elsa , Parra, Raquel FD van la, Teshome, Mediget , Hwang, Rosa F. , Miggins, Makesha, Piotrowski, Matthew J., Refinetti, Ana P, Ehlers, Richard A., Colen, Jessica Suarez, Loveland‐Jones, Catherine, Lesnikowski, Beth Ann, Samiian, Laila, Chong, Clayton, Arribas, Elsa M , Johnson, Helen Margaret , Shen, Yu , Krishnamurthy, Savitri , Smith, Benjamin D. , Lucci, Anthony , Sun, Susie X. , Shaitelman, Simona Flora , Boughey, Judy C. , Rauch, Gaiane M. , Group, Exceptional Responders Study, Candelaria, Rosalind P. , Adrada, Beatriz E. , Hunt, Kelly K. , Bedrosian, Isabelle

Mayo Clinic

JAMA Network Open | September 14, 2023 | Volume: 6 | Issue: 9 | Pages: e2333933

10.1001/jamanetworkopen.2023.33933 | PMID 37707811 Get It

ImportancePatients should have an active role in decisions about pursuing or forgoing specific therapies in treatment de-escalation trials.ObjectiveTo evaluate longitudinal patient-reported outcomes (PROs) encompassing decisional comfort and health-related quality of life (HRQOL) among patients who elected to enroll in a clinical trial evaluating radiotherapy alone, without breast surgery, for invasive breast cancers with exceptional response to neoadjuvant systemic therapy (NST).Design, Setting, and ParticipantsProspective, single-group, phase 2 clinical trial at 7 US medical centers. Women aged 40 years or older with invasive cT1-2 N0-1 M0 triple-negative or human epidermal growth factor receptor 2 (ERBB2)–positive breast cancer with no pathologic evidence of residual disease following standard NST enrolled from March 6, 2017, to November 9, 2021. Validated PRO measures were administered at baseline and 6, 12, and 36 months post-radiotherapy. Data were analyzed from January to February 2023.InterventionsPRO measures included the Decision Regret Scale (DRS), Functional Assessment of Cancer Therapy—Lymphedema (FACT-B+4), and Breast Cancer Treatment Outcomes Scale (BCTOS).Main Outcomes and MeasuresChanges in PRO measure scores and subscores over time.ResultsAmong 31 patients, the median (IQR) age was 61 (56-66) years, 26 (84%) were White, and 26 (84%) were non-Hispanic. A total of 15 (48%) had triple-negative disease and 16 (52%) had ERBB2-positive disease. Decisional comfort was high at baseline (median [IQR] DRS score 10 [0-25] on a 0-100 scale, with higher scores indicating higher decisional regret) and significantly increased over time (median [IQR] DRS score at 36 months, 0 [0-20]; P &amp;lt; .001). HRQOL was relatively high at baseline (median [IQR] FACT-B composite score 121 [111-134] on a 0-148 scale, with higher scores indicating higher HRQOL) and significantly increased over time (median [IQR] FACT-B score at 36 months, 128 [116-137]; P = .04). Perceived differences between the affected breast and contralateral breast were minimal at baseline (median [IQR] BCTOS score 1.05 [1.00-1.23] on a 1-4 scale, with higher scores indicating greater differences) and increased significantly over time (median [IQR] BCTOS score at 36 months, 1.36 [1.18-1.64]; P &amp;lt; .001). At 36 months postradiotherapy, the cosmetic subscore was 0.45 points higher than baseline (95% CI, 0.16-0.74; P = .001), whereas function, pain, and edema subscores were not significantly different than baseline.Conclusions and RelevanceIn this nonrandomized phase 2 clinical trial, analysis of PROs demonstrated an overall positive experience for trial participants, with longitudinal improvements in decisional comfort and overall HRQOL over time and minimal lasting adverse effects of therapy.Trial RegistrationClinicalTrials.gov Identifier: NCT02945579
Amyloid and tau‐PET in early‐onset AD: Baseline data from the Longitudinal Early‐onset Alzheimer's Disease Study (LEADS)
Cho, Hanna , Mundada, Nidhi S. , Apostolova, Liana G. , Carrillo, María C. , Shankar, Ranjani , Amuiri, Alinda, Zeltzer, Ehud , Windon, Charles , Soleimani‐Meigooni, David N. , Tanner, Jeremy A. , Lesman‐Segev, Orit H. , Aisen, Paul , Eloyan, Ani , Lee, Hye Sun , Hammers, Dustin B. , Kirby, Kala, Dage, Jeffrey L. , Fagan, Anne M. , Grinberg, Lea T. , Jack, Clifford R. , Kramer, Joel H. , Kukull, Walter A. , Vemuri, Prashanthi , Day, Gregory S. , Duara, Ranjan , Graff‐Radford, Neill R. , Masdeu, Joseph C. , Mendez, Mario F. , Onyike, Chiadi U. , Riddle, Meghan , Rogalskı, Emily , Salloway, Stephen , Sha, Sharon, Turner, Raymond Scott , Wingo, Thomas S. , Joie, Renaud La , Rabinovici, Gil D. , Jack, Clifford R , Vemuri, Prashanthi , Day, Gregory S , La Joie, Renaud , Grinberg, Lea , Rabinovici, Gil D , Windon, Charles , Wingo, Thomas S , Dage, Jeffrey L , Lawhn-Heath, Courtney A. , Hammers, Dustin B , Foroud, Tatiana , Murray, Melissa E. , Nudelman, Kelly , Toga, Arthur W. , Atri, Alireza , Duara, Ranjan , Honig, Lawrence S. , Jones, David T. , Masdeu, Joseph C , Musiek, Erik , Sha, Sharon J. , Wolk, David A. , Koeppe, Robert A. , Iaccarino, Leonardo , Dickerson, Bradford Clark

Mayo Clinic

Alzheimer's & Dementia | September 10, 2023 | Volume: 19 | Issue: S9 | Pages: No page available

10.1002/alz.13453 | PMID 37690109 Get It

Abstract INTRODUCTION We aimed to describe baseline amyloid‐beta (Aβ) and tau‐positron emission tomograrphy (PET) from Longitudinal Early‐onset Alzheimer's Disease Study (LEADS), a prospective multi‐site observational study of sporadic early‐onset Alzheimer's disease (EOAD). METHODS We analyzed baseline [18F]Florbetaben (Aβ) and [18F]Flortaucipir (tau)‐PET from cognitively impaired participants with a clinical diagnosis of mild cognitive impairment (MCI) or AD dementia aged < 65 years. Florbetaben scans were used to distinguish cognitively impaired participants with EOAD (Aβ+) from EOnonAD (Aβ−) based on the combination of visual read by expert reader and image quantification. RESULTS 243/321 (75.7%) of participants were assigned to the EOAD group based on amyloid‐PET; 231 (95.1%) of them were tau‐PET positive (A+T+). Tau‐PET signal was elevated across cortical regions with a parietal‐predominant pattern, and higher burden was observed in younger and female EOAD participants. DISCUSSION LEADS data emphasizes the importance of biomarkers to enhance diagnostic accuracy in EOAD. The advanced tau‐PET binding at baseline might have implications for therapeutic strategies in patients with EOAD. HIGHLIGHTS 72% of patients with clinical EOAD were positive on both amyloid‐ and tau‐PET. Amyloid‐positive patients with EOAD had high tau‐PET signal across cortical regions. In EOAD, tau‐PET mediated the relationship between amyloid‐PET and MMSE. Among EOAD patients, younger onset and female sex were associated with higher tau‐PET.